FBXO9 and leukemia: As AML is the second most common childhood leukemia, we utilized the TARGET pediatric study of 237 pediatric AML patients to analyze FBXO9 expression and again found downregulation of FBXO9 in all AML subtypes, except patients with normal karyotype (Figure 1C) [27].